NasdaqGS - Nasdaq Real Time Price USD

Tarsus Pharmaceuticals, Inc. (TARS)

41.84
+0.89
+(2.17%)
As of 12:35:11 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
233,674
182,953
17,447
25,816
57,027
Cost of Revenue
16,383
12,826
1,593
955
2,075
Gross Profit
217,291
170,127
15,854
24,861
54,952
Operating Expense
326,456
290,696
159,012
87,573
67,109
Operating Income
-109,165
-120,569
-143,158
-62,712
-12,157
Net Non Operating Interest Income Expense
6,272
7,165
6,991
1,300
36
Other Income Expense
-2,050
-2,150
274
-683
-1,651
Pretax Income
-104,943
-115,554
-135,893
-62,095
-13,772
Tax Provision
50
0
0
-4
55
Net Income Common Stockholders
-104,943
-115,554
-135,893
-62,091
-13,827
Diluted NI Available to Com Stockholders
-104,943
-115,554
-135,893
-62,091
-13,827
Basic EPS
-2.70
-3.07
-4.62
-2.52
-0.67
Diluted EPS
-2.70
-3.07
-4.62
-2.52
-0.67
Basic Average Shares
38,615.71
37,604.54
29,383.28
24,619.70
20,554.09
Diluted Average Shares
38,615.71
37,604.54
29,383.28
24,619.70
20,554.09
Total Operating Income as Reported
-109,165
-120,569
-143,158
-62,712
-12,157
Total Expenses
342,839
303,522
160,605
88,528
69,184
Net Income from Continuing & Discontinued Operation
-104,943
-115,554
-135,893
-62,091
-13,827
Normalized Income
-102,207
-112,818
-136,269
-61,322.05
-12,675.06
Interest Income
15,351
15,014
10,337
3,499
36
Interest Expense
8,572
7,447
3,225
2,064
0
Net Interest Income
6,272
7,165
6,991
1,300
36
EBIT
-96,371
-108,107
-132,668
-60,031
-13,772
EBITDA
-94,956
-106,882
-131,791
-59,705
-13,460
Reconciled Cost of Revenue
16,383
12,826
1,593
955
2,075
Reconciled Depreciation
1,415
1,225
877
326
312
Net Income from Continuing Operation Net Minority Interest
-104,943
-115,554
-135,893
-62,091
-13,827
Total Unusual Items Excluding Goodwill
-2,736
-2,736
376
-769
-1,578
Total Unusual Items
-2,736
-2,736
376
-769
-1,578
Normalized EBITDA
-92,220
-104,146
-132,167
-58,936
-11,882
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
-0.05
-426.06
12/31/2021 - 10/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IDYA IDEAYA Biosciences, Inc.
22.29
+0.04%
 
CNTA Centessa Pharmaceuticals plc
12.15
+0.91%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.88
-0.90%
 
SYRE Spyre Therapeutics, Inc.
17.41
-1.72%
 
EWTX Edgewise Therapeutics, Inc.
15.46
+0.26%
 
DYN Dyne Therapeutics, Inc.
14.45
-0.07%
 
SNDX Syndax Pharmaceuticals, Inc.
10.36
-2.95%
 
KRYS Krystal Biotech, Inc.
138.80
-1.09%
 
AKRO Akero Therapeutics, Inc.
54.71
+2.15%
 
ELVN Enliven Therapeutics, Inc.
22.34
+13.61%